Sign In
Buy SNDX
$19.32
+0.320 (+1.68%)
At Close: Jun 22, 2026
Syndax Announces Proposed Public Offering of Common Stock
04:31pm, Monday, 07'th Dec 2020
WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline
Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
12:30pm, Sunday, 06'th Dec 2020
WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript
01:28am, Tuesday, 03'rd Nov 2020
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript
